Johnson & Johnson has beefed up its vision portfolio over the past few years, and the effort appears to be paying off. Vision care sales reached $1.12 billion last quarter, up from $798 million in the year-earlier period, an increase of 34 percent when subtracting currency. When excluding that and an acquisition, revenue grew 9 percent, according to J.P. Morgan, as reported in CNBC.
The company has invested in vision as it refines its medical device group, adding surgical products and a contact subscription service to its lineup of Acuvue contact lenses.
The result is one of the fastest-growing platforms for J&J, particularly in medical devices, said Ashley McEvoy, company group chair of consumer medical devices.